Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Interpretation, Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Collaborating With Health System Partners to Review and Understand Trial Results
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Dissemination to Different “Customers”

CHAPTER SECTIONS

Collaborating With Health System Partners to Review and Understand Trial Results


Section 6

Dissemination to Different “Customers”

ExpandContributors

Gregory Simon, MD, MPH
Laura Mae Baldwin, MD, MPH
Sebastian Tong, MD, MPH
Carol Vance, PT, PhD

Dissemination of trial results to scientific audiences will necessarily focus on a small number of outcomes specified in advance. As discussed in Sections 1 and 2 of this chapter, dissemination to health system audiences, including either partners in a specific trial or leaders of other health systems, should typically consider a wider range of outcomes including resource use or cost, effects on patient or member satisfaction, effects on staff engagement or satisfaction, and effects on “report card” quality measures.

In some cases, health system leaders and frontline staff may focus on metrics or terminology different from those familiar to clinical or health services researchers. For example, when evaluating economic impact, researchers and research audiences may focus on incremental cost, incremental cost-effectiveness ratios, or graphical representation in cost-effectiveness planes. In contrast, health system leaders typically consider economic impact in terms of return on investment or changes in per-member-per-month expenditures.

The relative importance of different outcomes may vary across health systems or within health systems over time. For example, the relative importance of any specific quality metric may vary depending on a health system’s relative performance for that metric or the clinical areas identified as organizational priorities. Different health systems may vary in specific priorities regarding improving or maintaining staff satisfaction or engagement. Priority of specific outcomes may vary with changes in regulatory requirements, public reporting expectations, or financial incentives.

Investigators should understand the structure and business models of partner health systems. Scientific presentations of incremental cost or cost-effectiveness typically consider broader perspectives, such as total health services costs or overall societal costs. Health system decision-makers, however, typically consider a more local perspective. For example, a telephone-based care management program that reduces inpatient care could produce net gains for a health insurer but net losses for a hospital system providing care to those insured.

See also the Dissemination Approaches for Different Audiences chapter of the Living Textbook.

Previous Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction
  2. Early Engagement
  3. Learning Along the Way
  4. Early Debriefing
  5. Collaborative Analysis and Interpretation
  6. Dissemination to Different “Customers”


Version History

Published November 4, 2026

current section :

Dissemination to Different “Customers”

  1. Introduction
  2. Early Engagement
  3. Learning Along the Way
  4. Early Debriefing
  5. Collaborative Analysis and Interpretation
  6. Dissemination to Different “Customers”

Citation:

Collaborating With Health System Partners to Review and Understand Trial Results: Dissemination to Different “Customers”. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/dissemination/collaborating-with-health-system-partners-to-review-and-understand-trial-results/dissemination-to-different-customers/. Updated November 4, 2026.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map